Cipla launches etanercept biosimilar in India, but is it likely to overthrow Enbrel?

India-based pharmaceutical company Cipla announced last month that they were set to launch the first biosimilar of etanercept in India. The drug, ‘Etacept', would be used to treatment rheumatic disorders, and would offer a cheaper alternative to Amgen and Pfizer's hugely successful Enbrel brand (see Top 5 Best Selling Biologics of 2012). Cipla's Medical Director Dr Jaideep Gogtay said: "The …